Sign in to view content

Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)

Chirag D. Jhaveri, MD, FASRS

Video
Published 2021

Related

Ranibizumab for Radiation Retinopathy (RRR) A Prospective, Multicenter Trial of Monthly Versus PRN Dosing for Radiation Retinopathy-Related Macular Edema
Rajiv Anand, MD, FRCS, FASRS
Annual Meeting Talks
2018
Impact and Outcomes of Anti-VEGF Prior Authorization Requests: Insights From a Large Database Analysis
Saira Khanna, MD
Annual Meeting Talks
2023
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more